Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald D Perrone

Showing results (31-40 of 123) with videos related to

Pageof 13
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|July 28, 2018
Characterizing Approaches to Dialysis Decision Making with Older Adults: A Qualitative Study of NephrologistsKeren Ladin, Renuka Pandya, Ronald D Perrone, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2017
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life InstrumentDorothee Oberdhan, Jason C Cole, Holly B Krasa, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 4, 2018
Discussing Conservative Management With Older Patients With CKD: An Interview Study of NephrologistsKeren Ladin, Renuka Pandya, Allison Kannam, et al.
Kidney360|March 26, 2021
Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical TrialStephen L Seliger, Terry Watnick, Andrew D Althouse, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2021
The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A <i>Post Hoc</i> Analysis of the TEMPO 3:4 TrialJudith E Heida, Ron T Gansevoort, Vicente E Torres, et al.
Kidney Medicine|May 1, 2024
Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered RegistryElise Hoover, Vanessa Holliday, Nicole Merullo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 30, 2020
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Kidney International Reports|September 12, 2022
A Systematic Review of Reported Outcomes in ADPKD StudiesSara S Jdiaa, Nedaa M Husainat, Razan Mansour, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 27, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Kidney Medicine|April 17, 2025
Effectiveness of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in US Clinical Practice With Comparison to Historical Control DataRonald D Perrone, Diana Garbinsky, Sasikiran Nunna, et al.
Pageof 13

Showing results (31-40 of 123) with videos related to

Sort By:
Pageof 13
Clinical Journal of the American Society of Nephrology : CJASN|July 28, 2018
Characterizing Approaches to Dialysis Decision Making with Older Adults: A Qualitative Study of NephrologistsKeren Ladin, Renuka Pandya, Ronald D Perrone, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2017
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life InstrumentDorothee Oberdhan, Jason C Cole, Holly B Krasa, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 4, 2018
Discussing Conservative Management With Older Patients With CKD: An Interview Study of NephrologistsKeren Ladin, Renuka Pandya, Allison Kannam, et al.
Kidney360|March 26, 2021
Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical TrialStephen L Seliger, Terry Watnick, Andrew D Althouse, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2021
The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A <i>Post Hoc</i> Analysis of the TEMPO 3:4 TrialJudith E Heida, Ron T Gansevoort, Vicente E Torres, et al.
Kidney Medicine|May 1, 2024
Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered RegistryElise Hoover, Vanessa Holliday, Nicole Merullo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 30, 2020
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Kidney International Reports|September 12, 2022
A Systematic Review of Reported Outcomes in ADPKD StudiesSara S Jdiaa, Nedaa M Husainat, Razan Mansour, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 27, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Kidney Medicine|April 17, 2025
Effectiveness of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in US Clinical Practice With Comparison to Historical Control DataRonald D Perrone, Diana Garbinsky, Sasikiran Nunna, et al.
Pageof 13